Clinical trial
Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory…
NCT00079612 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00079612 |
|---|---|
| Title | Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer |
| Official title | Randomized Discontinuation Study of BAY 43-9006 in Patients With Advanced Refractory Cancer. |
| Lead sponsor | Bayer, Industry |
| Collaborators | Amgen Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Renal Cell |
| Intervention type | Drug |
| Interventions | Sorafenib (Nexavar, BAY43-9006), Placebo |
| Enrollment | 501 |
| Start date | Sep 1, 2002 |
| Completion | Jan 1, 2007 |
| First posted | Mar 11, 2004 |
| Last update posted | Dec 19, 2014 |
| Countries | United Kingdom, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: